Researchers at Stanford University have developed a method and composition of immunomodulatory compounds that prevent and reverse T cell exhaustion, improving on existing CAR T cell therapies.
Psoriasis is a chronic skin inflammatory disease that affects 7.5 million people in the US and accounts for $1.2 billion in annual direct medical costs.